Approved product traction ZYNLONTA is a marketed antibody drug conjugate with FDA accelerated approval and European conditional approval for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of therapy. This establishes a credible commercial foothold and creates opportunities to expand into earlier lines and additional combinations, as well as payer and access discussions with regional partners.

ADC platform partnerships ADC Therapeutics emphasizes end-to-end capabilities from clinical development through manufacturing and commercialization, positioning it as a potential partner or CDMO for other companies seeking ADC design, conjugation, and scale-up expertise—especially as they pursue next-generation targets like PSMA.

Financial backing A solid revenue base and recent equity financing signal capacity to support milestone-driven collaborations and regional commercialization deals. Consider structuring partnerships with upfronts, milestones tied to regulatory or sales goals, and potential co-investment, while conducting due diligence given ongoing regulatory scrutiny.

Global reach With headquarters in Switzerland and operations in the United States, the company is well positioned for multi-regional partnerships, enabling regional distribution, supply agreements, and localized clinical collaborations to expand ZYNLONTA uptake and future ADC programs.

Leadership leverage As a recognized global leader in ADCs with ongoing trials and high-profile industry presence, the company can leverage its established brand, data generation, and collaboration history to pursue co-development, licensing, or strategic distribution deals with oncology players seeking a validated ADC platform.